In Vivo Human Study on Commercial Cellobiose as a Potential Prebiotic Candidate
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- Change in absolute abundance of faecal Bifidobacterium spp. and Lactobacillus spp.
研究概览
简要总结
The goal of this project is to investigate whether cellobiose, a type of sugar, has a beneficial effect on gut health when consumed by humans. Cellobiose will be obtained from spent coffee grounds through enzymatic modification, repurposing waste biomass for a potentially valuable purpose. The study will only focus on conducting in vivo human trials using a commercial form of cellobiose from Savanna Ingredients GmbH, which has recently been approved as a novel food by the EU (https://eur-lex.europa.eu/eli/reg_impl/2023/943/oj)
We will also be testing two other commercial products: Orafti® P95, an oligofructose-based product from Beneo GmbH, and maltodextrin from Special Ingredients Limited. These products will be compared to evaluate their potential in promoting gut health by nourishing beneficial bacteria, The study will involve feeding these products to volunteers and observing their impact on gut health.
The key questions this project aims to address include:
- Does cellobiose, exhibit any gut health promoting effects in humans?
- How does cellobiose compare to other commercial prebiotic products, such as Orafti® P95, in terms of its effects on gut health?
To conduct the study, volunteers will be provided with the three different products to consume over a specified period. Their faecal samples will be collected at various points to assess changes in gut microbiota composition and other indicators of gut health. This will involve close monitoring of participants' health and adherence to ethical guidelines to ensure their safety and well-being throughout the study.
Overall, this project seeks to expand our understanding of the potential health benefits of cellobiose and other prebiotic carbohydrates. It aims to provide valuable insights into the role of these substances in promoting gut health.
详细描述
In this randomised, double-blinded, parallel-group trial, the investigators will enroll 36 healthy adult volunteers and randomise them 1:1:1 to one of three dietary-supplement arms. Participants will consume their assigned product once daily-5 g during a one-week adaptation phase followed by 10 g/day for a three-week intervention phase. Faecal samples will be collected at baseline (Visit 1) and at study completion (Visit 5). Total bacterial counts will be determined by fluorescence in situ hybridisation coupled with flow cytometry (FISH-FLOW), and short-chain fatty acid concentrations quantified by gas chromatography-flame ionisation detection (GC-FID).
The primary outcomes are the change from baseline to Visit 5 in (1) absolute abundance of Bifidobacterium spp. and Lactobacillus spp., and (2) total faecal short-chain fatty acid concentration. Secondary outcomes include gut microbiota diversity metrics (α- and β-diversity) and daily gastrointestinal symptom incidence. Exploratory outcomes will assess correlations between shifts in specific bacterial taxa and metabolite profiles, as well as changes in the abundance of other key genera.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Inclusion criteria:
- •Participants aged 18 years old and above
- •Participants are willing to comply with the study instructions
- •Participants have a stool frequency of at least 3 bowel movements per week
- •Participants are healthy at the time of signing the consent form
排除标准
- •Not pregnant or planning to be pregnant
- •Previously or currently diagnosed gastrointestinal diseases and disorders that might affect the gut environment.
- •Food allergies or intolerances
- •Previously or currently diagnosed with cancer or taking a long-term medication.
- •Use of medication (e.g, antibiotics, aspirin, proton pump inhibitors) influencing gastrointestinal function (8 weeks before intervention)
- •Participants are currently involved or will be involved in another clinical or food study
研究组 & 干预措施
Orafti P95 (oligofructose P95)
Healthy adult volunteers will consume 5 g/day of Orafti P95 (oligofructose, Beneo GmbH) mixed in water for the first 7 days, and consume 10 g/day of Orafti P95 (oligofructose, Beneo GmbH) mixed in water for the rest of the 21 days.
干预措施: Oligofructose P95 (Dietary Supplement)
Cellobiose
Participants receive 5g/day for the first 7 days and 10 g/day cellobiose for 21 days.
干预措施: Cellobiose (Dietary Supplement)
Maltodextrin
Participants receive 5 g/day for the first 7 days and 10 g/day maltodextrin for the rest of the 21 days as a non-prebiotic control.
干预措施: Maltodextrin (Placebo) (Dietary Supplement)
结局指标
主要结局
Change in absolute abundance of faecal Bifidobacterium spp. and Lactobacillus spp.
时间窗: Baseline (Day 0; Visit 1) to end of the intervention period (Day 28; Visit 5)
Absolute abundance of Bifidobacterium spp. and Lactobacillus spp. in faecal microbiota, determined by 16S rRNA gene sequencing (Illumina NGS sequencing) and FLOW-FISH for total bacterial counts
Change in total faecal short-chain fatty acid concentration
时间窗: Baseline (Day 0; Visit 1) to end of the intervention(Day 28; Visit 5)
Sum of acetate, propionate, and butyrate concentrations in faecal samples, measured by GC-MS.
次要结局
- Magnitude and pattern of overall gut-microbiota shifts from V1 to V5(Baseline (V1) through end-point (V5) of the 28-day intervention)
- Number of participants with Gastrointestinal Tolerability & Safety(Days 1 through 28 of the intervention period)
研究者
Manxi Huang
PhD Candidate, Department of Food and Nutritional Sciences
University of Reading